You are here

Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance

Last updated on October 4, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacterial Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT01788449
Pfizer
Completed
Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pneumococcal Infections
NCT03512288
All Genders
0+
Years
Multiple Sites
Cryptococcal Meningitis, HIV Infections
NCT00002068
All Genders
13+
Years
Multiple Sites
Pneumococcal Infections, COPD
NCT03276754
All Genders
18+
Years
Multiple Sites
Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance
Association of Antibiotic Measures and Control of Bacterial Resistance
Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.
Primarily, this study is designed to assess the efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of extended-spectrum betalactamases (ESBLs) producing E.coli or K pneumoniae, S aureus methicillin resistant (MRSA) and Enterococcus vancomycin resistant (VRE). Secondly, this study plans to determine the acquisition rate of ESBL producing E Coli or K pneumoniae, methicillin resistant S Aureus (MRSA) and vancomycin resistant Enterococcus spp (VRE), both pre- and post-intervention.
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Intensive Care Unit (ICU)
Bacterial Infections
Not Provided
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
335
February 2007
February 2007   (Final data collection date for primary outcome measure)
All patients admitted in ICU will be enrolled (who qualify for treatment).
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01788449
0910X-101852
No
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
February 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now